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Conserved tau microtubule-binding repeat histidines confer pH-dependent 
tau-microtubule association  
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ABSTRACT 
 
Tau, a member of the MAP2/tau family of 
microtubule-associated proteins, functions to 
stabilize and organize axonal microtubules in 
healthy neurons. In contrast, tau dissociates 
from microtubules and forms neurotoxic 
extracellular aggregates in neurodegenerative 
tauopathies. MAP2/tau family proteins are 
characterized by three to five conserved, 
intrinsically disordered repeat regions that 
mediate electrostatic interactions with the 
microtubule surface. We use molecular 
dynamics, microtubule-binding experiments 
and live cell microscopy to show that highly 
conserved histidine residues near the C 
terminus of each MT-binding repeat are pH 
sensors that can modulate tau-MT interaction 
strength within the physiological intracellular 
pH range. At lower pH, these histidines are 
positively charged and interact with 
phenylalanine residues in a hydrophobic cleft 
between adjacent tubulin dimers. At higher pH, 
tau deprotonation decreases microtubule-
binding both in vitro and in cells.  However, 
electrostatic and hydrophobic characteristics of 
histidine are required for tau-MT-binding as 
substitution with constitutively positively 
charged, non-aromatic lysine or uncharged 
alanine greatly reduces or abolishes tau-MT 
binding. Consistent with these findings, tau-MT 
binding is reduced in a cancer cell model with 
increased intracellular pH but is rapidly 
rescued by decreasing pH to normal levels. 
Thus, these data add a new dimension to the 
intracellular regulation of tau activity and 
could be relevant in normal and pathological 
conditions. 
 
 
Neuronal development and function rely on a 
class of structural microtubule (MT)-associated 
proteins (MAPs) that share conserved MT-binding 
motifs. These MAP2/tau family proteins associate 
with MTs in an extended conformation along the 
MT protofilament ridge (1, 2), and binding is 
thought to be mediated largely through 
electrostatic interactions of basic amino acids 
distributed throughout the MAP2/tau family MT-
binding repeats with the negatively charged MT 
wall. Tau (MAPT), the most intensely studied 
member of the MAP2/tau family, is expressed in 
both the developing and adult nervous system, and 
different tau splice variants contain either three or 
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four MT-binding repeats (3). In adult neurons, tau-
MT binding is restricted to the axon. Tau is 
thought to influence MT stability and mechanics 
and to regulate axonal transport potentially by 
organizing inter-MT spacing in the axonal MT 
bundle (4–6), but its physiological function and 
regulation is still poorly understood. 
Tau is also a key player in progressive 
neurodegenerative diseases, such as Alzheimer’s 
disease and frontotemporal dementia. These and 
other tauopathies are characterized by a loss of 
axonal tau-MT association and an abnormal 
extracellular accumulation of aggregated tau (7, 8) 
although it remains controversial if these tau 
neurofibrillary tangles are a cause or consequence 
of neurodegeneration. Both the spatial control of 
tau-MT binding in normal neurons and the 
pathological dissociation from MTs highlight the 
importance of understanding how tau-MT-binding 
is controlled. Tau has many phosphorylation sites 
and as is the case with other MT-binding proteins, 
tau phosphorylation decreases its affinity for MTs, 
and pathological tau aggregates are formed by all 
splice variants of hyperphosphorylated tau (8, 9). 
However, the intracellular environment is 
complex and many incompletely understood 
factors contribute to the control of protein 
interactions and functions (10). One such 
underappreciated regulator is intracellular pH 
(pHi) (11). In contrast to previous static views of 
pHi homeostasis, we now know that pHi is 
dynamic and changes, for example, during cell 
cycle progression (12, 13), cell adhesion (14, 15), 
and migration  (16–18). In addition, dysregulated 
pHi is a feature of many diseases, including cancer 
(19, 20) and neurodegenerative disorders (21, 22). 
Although protein pH sensitivity is generally 
mediated by histidines with a pKa near neutral, 
other titratable residues can also play critical roles 
depending on the protein energy landscape and 
cooperativity (11). Consequently, several 
examples have emerged in which histidine 
protonation dynamics regulate protein-protein (23, 
24), protein-nucleotide (25), and protein 
phospholipid interactions (26, 27). Because all 
MAP2/tau family MT-binding repeats contain 
invariant histidine residues, we used in silico, in 
vitro and in vivo methods to ask if tau-MT binding 
is sensitive to changes in pHi. Consistent with the 
modulation of electrostatic interactions, we find 
that tau-MT-binding is decreased at increased pH, 
which opens new directions for understanding tau-
MT binding dynamics in normal and pathological 
cell behaviours. 
 
RESULTS 
Conserved histidine residues contribute to 
tau-MT interactions 
Recent cryo-electron microscopy (cryo-EM) 
data of MT-bound tau at near atomic resolution 
(28) indicate that tau-MT interactions extend 
beyond the central KxGS MT-binding repeat 
motif. In particular, the structure of the second tau 
MT-binding repeat (R2) shows that a highly 
conserved histidine residue, His299, near the R2 
C-terminus may contribute to tau-MT binding. 
His299 points into a hydrophobic cleft defined by 
β-tubulin Phe399 and Phe395 near the interdimer 
interface, and His299 is in a T-shaped 
configuration with Phe399 (Fig. 1C).  
Because of the negative electrostatic potential 
of the MT surface (Fig. 1A), the pKa of His299 is 
estimated to be upshifted to about 7.0 when 
compared with the imidazole group in solution 
that has a pKa of 6.3 (29). A positively charged 
His299+ imidazolium cation is further stabilized 
by favorable electrostatic interactions with 
negatively charged β-tubulin Glu442 and is within 
reach of other hydrophobic contacts (< 7 Å) with 
β-tubulin residues near the inter-tubulin dimer 
cleft (Fig. 1C). Based on this analysis, we 
predicted that His299 is positively charged at 
neutral pH. His299 protonation could thus be 
regulated through changes in pH that fall within 
the physiological range. In contrast, solvent-
exposed lysine and arginine residues in the MT-
binding repeats have pKa values >10 and are 
always protonated near neutral pH values. We 
therefore asked how positively charged His299+ or 
neutral His2990 could affect the interaction 
between tau R2 and MTs by in silico molecular 
dynamics (MD). 
Based on the cryo-EM structure, we built 
models of the tau R2-MT complex with different 
His299 protonation states. Both systems were then 
evaluated in short time MD simulations (5 ns). In 
the model containing positively charged His299+, 
the T-shaped interaction with Phe399 was 
maintained throughout the entire simulation (Fig. 
1C; supplementary Video S1), with distances not 
exceeding 5 Å and in agreement with the cryo-EM 
structure. In contrast, neutral His2990 turned away 
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from the hydrophobic cleft and remained in this 
position during the MD simulation. This also 
caused higher deviation from the tau-MT cryo-EM 
structure (RMSD = 2.9 Å) when compared with 
His299+ (RMSD = 1.9 Å) as well as globally 
increased conformational fluctuations in both 
tubulin and tau (supplementary Fig. S1). Although 
our simulations analyzed only the one of the 3-4 
tau MT-binding repeats for which a cryo-EM 
structure was available, the MT-binding repeat 
histidine residues in positions equivalent to His299 
are highly conserved (Fig. 1D) (1, 2). In addition, 
3R and 4R tau isoforms bind MTs in a similar 
manner utilizing the full length of the respective 
MT-binding repeat region (30). Because 
individually weak MT-binding repeats act together 
to support high affinity tau-MT interactions (31), 
histidine deprotonation at increased pH in multiple 
repeats may thus cooperatively weaken the tau-
MT interaction and consequently destabilize the 
tau-MT complex. 
Increased pH decreases tau-MT binding 
To test the hypothesis that increased pH 
weakens tau-MT binding, we first used an in vitro 
MT co-sedimentation assay. The standard PIPES 
buffer used in such assays has a pKa of 6.8, which 
is at the low end of the physiological pH range. 
Therefore, we instead incubated 100 nM purified 
0N3R tau protein, a developmental tau isoform 
that contains three MT-binding repeats with 0.5 
µM paclitaxel-stabilized MTs in a MOPS-based 
buffer (pKa = 7.2) that provides better buffering 
capacity in the relevant range. MT-bound tau was 
then separated from soluble tau protein by 
centrifugation through a glycerol cushion. Nearly 
all tau bound to MTs at pH 7.1 (99.5 ± 0.2%; 
mean ± SD; Fig. 2A). In contrast, the amount of 
tau in the MT pellet was significantly reduced at 
pH 7.8 to 91.7 ± 3.4%, and a detectable fraction of 
unbound tau remained in the supernatant.  
Because this was a relatively small difference 
likely due to near saturation of the binding 
reaction at these concentrations, we next 
determined the apparent dissociation constant (Kd) 
of tau-MT binding at pH 7.1 and pH 7.8. To 
quantify the amount of MT-bound tau protein 
more accurately than we were able to achieve by 
immunoblot and densitometry, we instead used a 
fluorescently tagged 0N3R sfGFP-tau. The 
fraction of MT-bound sfGFP-tau was determined 
by measuring the fluorescence of sfGFP-tau that 
remained in the supernatant and that co-
sedimented with MTs, varying the MT 
concentration over approximately two orders of 
magnitude around the anticipated Kd (32). Using 
hyperbolic curve fitting to a binding isotherm, we 
calculated a Kd of 0.11 ± 0.014 µM (mean ± SD; 
Fig. 2B) at pH 7.1. This reflects a slightly higher 
0N3R affinity for MTs compared to reported 
values (32), which may be due to our different and 
lower salt buffer conditions. Importantly however, 
at pH 7.8, the measured Kd was significantly 
increased by approximately 2-fold (0.2 ± 0.013 
µM) indicating that the affinity of tau for MTs is 
decreased at increased pH within the physiological 
intracellular pH range. 
Intracellular pH modulates tau-MT binding 
in cells 
In vitro experiments cannot fully reconstitute 
the intracellular milieu or the effect of 
posttranslational modifications (10). In addition, 
taxanes used to stabilize MTs in vitro alter tau-MT 
interactions (33). We therefore next asked whether 
changes in pHi alter tau-MT binding in human 
retinal pigment epithelial (RPE) cells transiently 
expressing mEmerald-tagged 0N3R tau (Em-tau) 
at a low level that did not induce MT bundling. 
pHi changes were measured in parallel in 
untransfected cells (34, 35). In control pH 7.4 
HEPES buffer, the pHi of RPE cells was ~7.4 and 
Em-tau clearly bound along MTs although a 
substantial fraction of Em-tau remained in the 
cytoplasm. Acute increase of pHi to ~7.7 by 
addition of 20 mM NH4Cl resulted in a notable 
decrease in MT-bound tau (Fig. 3A; 
supplementary Video S2). Because of low 
amounts of MT-bound tau at high pHi and 
movement of the MT network in these time-lapse 
sequences, direct measurements of MT-bound tau 
were difficult and unreliable. Therefore, we 
instead quantified Em-tau fluorescence intensity in 
the cytoplasm. It is important to note that the 
reported pKa of mEmerald is ~6.0 and mEmerald 
fluorescence is virtually insensitive to pH changes 
above 7.0 (36). Indeed, we did not observe an 
increase in total cell fluorescence when pHi was 
increased within the physiological range. Thus, the 
observed increase in cytoplasm Em-tau 
fluorescence in response to experimentally 
increased pHi reflects dissociation from MTs. Em-
tau dissociation from MTs occurred within 
seconds and was rapidly reversed when the NH4Cl 
pH-modulated tau-microtubule binding 
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solution was washed out and replaced with control 
HEPES buffer lowering pHi to its normal value. 
In contrast, the MT network was not affected 
by these acute pHi changes as quantified by 
measuring the cytoplasm fluorescence intensity of 
EGFP-tagged tubulin not incorporated into MTs 
(Fig. 3). This demonstrates that Em-tau 
dissociation from MTs at elevated pHi was not a 
consequence of MT depolymerization, and that the 
overall polymerization state of the MT network is 
insensitive to short-term pHi changes within this 
range although we did not directly test MT plus 
end growth dynamics. 
We observed a similar rapid and reversible 
disruption of Em-tau binding to MTs when pHi 
was acutely increased with 100 mM NaCl (Fig. 4), 
which osmotically activates proton efflux by the 
plasma membrane Na+-H+ exchanger NHE1 (34, 
35). Tau belongs to the MAP2/tau family of 
microtubule-associated proteins (MAPs) that share 
the same repeat motif in the MT-binding domain 
(1), and the histidine residues at the C-termini of 
MT-binding repeats in all these proteins are 
remarkably conserved (Fig. 1D). To test whether 
other MAP2/tau family proteins respond to 
intracellular pHi changes, we transiently expressed 
the MT-binding region of mouse MAP4 
containing three MT-binding repeats in RPE cells. 
Like Em-tau, Em-MAP4 responded to 
hyperosmotic pHi increase with a reversible 
decrease in MT-binding (Fig. 4) indicating that 
decreased MT binding at increased pHi may be a 
common characteristic of MAP2/tau family 
proteins. 
The above experiments relied on acute 
changes in pHi that occur within seconds to 
minutes. To test how long-term pHi changes 
affected tau-MT interactions, we transiently 
expressed Em-tau in MCF10A mammary 
epithelial cells stably expressing an estrogen 
receptor-induced oncogenic H-RasV12 (ER-
RasV12). We previously showed that tamoxifen-
induced RasV12 expression increased pHi to 
almost 7.7 within 24 hours (37). We found that 
Em-tau was predominantly cytosolic in tamoxifen-
induced RasV12-expressing cells. However, 
acutely decreasing pHi with a pH 7.2 buffer 
containing the protonophore nigericin, which 
equilibrates extracellular and intracellular pH, 
resulted in a rapid rescue of Em-tau binding to 
MTs (Fig. 5). Together these data demonstrate that 
an increase in pHi within the physiological range 
weakens tau-MT binding, which in cells results in 
substantially decreased MT-associated tau. 
Histidines confer pH sensitivity and are 
required for interactions with MTs  
The location of His299 within a hydrophobic 
pocket indicates that hydrophobic interactions of 
the histidine aromatic ring are important for MT 
binding, and may explain the high degree of 
conservation of these histidine residues. To further 
investigate this, we sought to identify mutations 
that mimic His2990 and His299+ in a pH-
independent manner. We therefore built a model in 
which His299 was changed to a  constitutively 
positively charged lysine residue that we 
hypothesized could mimic His299+. However, MD 
simulations showed that a lysine substitution 
behaved more like deprotonated His2990 
(supplementary Fig. S1). While protonated lysine 
cation-π interactions are strong and commonly 
observed in proteins (38), due to the high entropic 
desolvation cost, the β tubulin hydrophobic cleft 
near Phe395 and Phe399 cannot readily 
accommodate the hydrophilic lysine ammonium 
cation. In fact, Lys299 turns away from the 
hydrophobic cleft although it can maintain 
electrostatic interactions with Glu422 (Fig. 6A).  
To further evaluate the importance of 
hydrophobic contacts by in silico MD, we next 
analyzed a substitution of His299 with alanine, a 
small non-charged amino acid that is not expected 
to contribute to either hydrophobic or electrostatic 
interactions. Like lysine, the alanine substitution 
also showed increased fluctuations of the tau-MT 
complex near the C-terminus of tau R2 
(supplementary Fig. S1), and throughout the MD 
simulation Ala299 pointed away from the 
hydrophobic cleft (Fig. 6A; supplementary Video 
S3). 
While we cannot directly infer binding free 
energy changes from MD, our in silico models 
support that the positively charged His299+ can 
uniquely form both an electrostatic interaction 
with Glu422 and an energetically favorable 
interaction with Phe399. In contrast, lysine at 
position 299 only maintains the electrostatic 
interaction while an Ala299 loses both resulting in 
partial dissociation of the tau peptide from the MT 
surface. 
To directly test that conserved histidines are 
required for tau-MT-binding, we generated mutant 
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tau 0N3R protein in which all four histidine 
residues in the MT-binding repeats (R3 has two 
adjacent histidines) were substituted with either 
lysine (4H>K) or alanine (4H>A). If MT-binding 
relied only on electrostatic interactions with 
protonated histidines, tau(4H>K) MT-binding 
would be expected to be similar to wild-type tau, 
while tau(4H>A) should show reduced MT-
binding. Instead, and consistent with our structural 
analysis, both variants displayed substantially 
reduced MT binding in vitro (Fig. 6B). Although 
tau(4H>K) seemed to bind to MTs somewhat 
better than tau(4H>A), in vitro this difference was 
not statistically significant.  
If these conserved histidines are responsible 
for the pH sensitivity of tau-MT binding, because 
of the high pKa of lysine, residual Tau(4H>K) 
binding to MTs should no longer respond to pH 
changes within the physiological range. Because 
the Kd values we measured for pH-modulated tau-
MT binding were in the 100-200 nM range (Fig. 
2B), we tested this at a 20-fold lower tau to MT 
ratio that should be well below saturation. At these 
low tau concentrations (10 nM), it was not 
possible to accurately determine the amount of tau 
remaining in the supernatant. Instead we compared 
how much tau was recovered in the MT pellet at 
pH 7.8 and pH 7.1, which was reduced to 52.8 ± 
18.3% (mean ±SD; Fig. 6C). As a control, the 
amount of MTs in the pellet remained unchanged 
indicating that this difference reflects tau-MT-
binding and not a decrease in MT stability at 
higher pH. In contrast to wild-type tau, MT-
binding of tau(4H>K) was not decreased at 
increased pH (112.5 ± 8.1%; Fig. 6C), and the pH 
7.8 to pH 7.1 ratio was not significantly different 
from the amount of MTs recovered in the pellet. 
Lastly, we tested binding of fluorescently 
tagged tau variants to MTs in RPE cells expressing 
equivalent levels of wild-type or mutated Em-tau 
(Fig. 7; supplementary Fig. S2). In cells, binding 
of Em-tau(4H>K) to MTs was significantly 
reduced compared with wild-type tau, and Em-
tau(4H>A) did not bind MTs at all. Together, 
these data confirm that conserved histidine 
residues in the tau MT-binding repeats are 
required for tau MT-binding that are not solely 
explained by electrostatics, and protonation of 
these histidines can be titrated to modulate tau-MT 
interactions. 
 
DISCUSSION 
We used multiple approaches including MD 
simulations and MT binding assays in vitro and in 
cells to show that interactions of MAP2/tau family 
proteins with MTs are sensitive to pH changes 
within the physiological intracellular range. We 
also demonstrate that histidine residues near the C-
terminal end of MAP2/tau family MT-binding 
repeats are essential. Tau mutants with these 
histidines substituted with either lysine or alanine 
show reduced or completely absent MT-binding in 
cells. In addition, at least in vitro these conserved 
histidines mediate pH sensitivity as replacing them 
with lysine residues, which are insensitive to pH 
changes in the physiological range, abolishes pH-
modulation of MT-binding in vitro. However, we 
were not able to test this rigorously in cells 
because of the already substantially reduced MT-
binding of the H>K mutant. 
Although these MAP2/tau MT-binding repeat 
histidine residues are highly conserved, their 
importance has not been recognized because the 
intrinsically disordered nature of MAP2/tau family 
proteins complicates structural analysis. Previous 
studies did not resolve MT-bound peripheral 
regions of these MT-binding repeats and 
predominantly found MAP2/tau family densities 
along the MT protofilament ridge (2). Although a 
high-definition model of native MT-bound tau is 
still not available, recent cryo-EM data of MT-
bound constructs of human tau MT-binding repeat 
R2 show a close interaction of His299 with the 
tubulin interdimer interface (28). This overall 
arrangement of tau histidine residues near tubulin-
tubulin interfaces is also supported by NMR and 
more recent electron paramagnetic resonance 
spectroscopy data (30, 39).  
At low pH, our structural and MD analysis 
defines a stable interaction of the protonated 
histidine with specific aromatic residues in β-
tubulin H11. This requires the amphiphilic 
character of protonated histidine as deprotonation 
at high pH or substitution with either non-aromatic 
or non-charged amino acids substantially weakens 
tau-MT interactions. Thus, our data are consistent 
with older biochemical crosslinking data showing 
tau interaction with H11, H12 and the flexible 
loop connecting these helices (40) and new 
ultrastructural analysis of MT-bound MAP4 that 
indicates a strong contribution of the tubulin 
pH-modulated tau-microtubule binding 
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interdimer interface to the overall MAP4-MT 
binding energy (41). 
Cation-π interactions between aromatic rings 
and positive charges are common in proteins, and 
histidine-aromatic complexes are energetically 
favorable in the hydrophobic protein interior (38, 
42, 43). Despite its unusual arrangement for a 
cation-π interaction with the edge of Phe399 
pointing toward the His299 ring, we find that 
protonated His299+ maintains this proximity and 
geometry throughout 5 ns MD simulations. Given 
that the positive charge is not located above the π 
system, we propose that this unusual geometry 
may be stabilized by additional electrostatics. The 
Amber force field used in our simulations does not 
explicitly compute cation-π interactions, but it 
indirectly accounts for them by including both 
electrostatics and van-der-Waals energies. Our 
MD calculations are focused on how tau-MT 
interactions are modulated, but it is plausible that 
His299 protonation influences the unbound tau 
conformation, which could contribute to tau-MT 
net binding affinities. However, quantitative 
estimates of such relative free energies are 
challenging and were not attempted here. 
Because of its role in neurodegenerative 
disease, tau is the most widely studied member of 
the MAP2/tau family, and much research has 
focused on the role of tau aggregation in 
Alzheimer’s disease and related tauopathies with 
over 14000 publications listed in PubMed (3). 
Less is known about how MAP2/tau family 
proteins control the MT cytoskeleton in normal 
neurons. In vitro, tau promotes MT polymerization 
and protects MTs from disassembly likely by 
spanning multiple tubulin dimers and thus 
inhibiting their dissociation. Consequently, 
MAP2/tau family proteins are thought to stabilize 
MTs in neurons. Recent data of shRNA-mediated 
tau depletion in primary neurons indicate that tau 
promotes growth cone MT elongation (44). In 
addition, tau inhibits EB1 association with 
growing MT ends (45) suggesting a multiple roles 
of tau in controlling neuronal MT polymerization 
dynamics. High levels of MAP2/tau family 
proteins induce MT bundles in non-neuronal cells 
with inter-MT spacing similar to neurite MT 
bundles (6). Binding of MAP2/tau family proteins 
along MTs also inhibits MT motor movements (5). 
However, these functional data rely mostly on in 
vitro experiments or MAP2/tau protein 
overexpression, and to what extent these reflect 
physiological neuronal tau functions remains 
unclear. For example, MT-based transport appears 
unaffected in tau knock-out mice (46), and 
moderate tau expression levels have little effect on 
MT network organization. In summary, much 
remains to be learned about how MAP2/tau 
proteins control physiologically normal neuronal 
MT cytoskeleton function. What we do know 
though is that neurons are morphologically 
complex and thus the activity of neuronal 
cytoskeleton proteins must be controlled precisely.  
Characteristic of many intrinsically disordered 
proteins are their complex phosphorylation 
patterns. MAP2/tau proteins are no exception (3, 
47) and phosphorylation within the MT-binding 
repeats generally reduces tau MT-binding, 
consistent with electrostatic repulsion between 
negatively charged phosphates and the strong 
negative electrostatic field of the MT surface. We 
propose that the upshifted pKa of the conserved 
MT-binding repeat histidine residues allows them 
to act as pH sensors and modulate tau-MT 
electrostatic interactions within the physiological 
pH range. Consistent with a decreased tau-MT 
interaction strength, individual tau molecules also 
show increased diffusion along MTs at increased 
pH (48). Thus, pHi changes may add another layer 
of control to MAP2/tau MT-binding. Observed 
differences in the magnitude of pH-modulated tau 
MT-binding between our experiments in vitro and 
in cells may be due to partial phosphorylation of 
tau in cells. However, tau-binding to MTs is also 
sensitive to subtle changes in MT lattice geometry 
(33). Although we find that the total MT polymer 
is insensitive to short-term pHi changes, we cannot 
rule out that pH-mediated conformational changes 
of the MT wall contribute to pH-sensitive tau-MT 
interactions. 
Currently, we can only speculate as to the 
physiological relevance of pH modulating tau-
MT-binding. Because neurons are 
morphologically differentiated with highly 
compartmentalized cytoplasm, it is possible that 
developmental or spatial control of pHi in 
developing neurons contributes to spatiotemporal 
control of MAP2/tau activities, but potential local 
differences in neuronal cytoplasmic pHi remain 
poorly characterized (49, 50). However, 
acidification of the neuronal cytoplasm has been 
associated with and speculated to be a causative 
pH-modulated tau-microtubule binding 
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agent in neurodegeneration (21). Our current data 
would predict enhanced tau-MT binding in 
acidified neurons, which is inconsistent with tau 
aggregation due to weakened tau-MT interactions 
in Alzheimer’s disease. Alternatively, increased 
binding of protonated tau to negatively charged 
phospholipid membranes may increase toxic 
effects of aggregated tau (51). 
Lastly, ectopic tau expression has been 
described in many types of cancer and elevated tau 
levels appear to correlate with aggressive 
metastatic cancer phenotypes and resistance to 
taxane chemotherapy (52–54). Cancer cells 
generally have elevated pHi (19, 20) although a 
large variability in different types of cancers is 
likely. Our data indicate that tau-MT-binding is 
greatly reduced in a breast cancer model driven by 
oncogenic RasV12 and is rapidly rescued by 
returning pHi to a physiological normal level. 
Thus, we would predict that taxane sensitivity 
positively correlates with pHi in tau-expressing 
cancers, which could serve as a diagnostic tool for 
taxane chemotherapy. In conclusion, even though 
we do not yet understand the functional relevance 
of pH-modulated tau-MT interactions in normal or 
pathological conditions, the current study adds 
another facet to the already complex regulation of 
MAP2/tau cell biology.  
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EXPERIMENTAL PROCEDURES 
Molecular dynamics – The recently reported 
cryo-EM structure of MT-bound tau MT-binding 
repeat 2 (amino acids 274-300; PDB ID: 6CVN) 
was used as starting point for MD simulations 
(28). The pKa of MT-bound His299 was predicted 
using the PROPKA3 software (29). Two different 
protonation states for His299 were modeled, a 
neutral His2990 protonated on the ε nitrogen, as 
predicted by the Maestro Protein Preparation 
package, and a double protonated form, His299+. 
His299 was also mutated to lysine or alanine using 
the ‘swappa’ command as implemented in 
Chimera (55). Preceding MD simulations, the tau-
MT model structures were submitted to 1,000 
steps of steepest descent minimization, followed 
by 1,000 ps of equilibration. The SHAKE 
algorithm was used to constrain all bonds 
containing hydrogen atoms. A cut-off of 12 Å was 
used for long-range interactions. These energy-
minimized models were then submitted to short 
time MD simulations (5 ns) using the NPT 
ensemble with the Amberff12SB force field (56). 
The Berendsen pressure coupling scheme was 
used for keeping the pressure constant at 1 atm. 
The temperature of the production was constant at 
310K using the Langevin thermostat.  
Plasmids and protein production – 
Mammalian expression plasmids mEmerald-
MAPTau-C-10 (encoding full-length human tau 
isoform 4; accession number NM_016841) and 
mEmerald-MAP4-C-10 (containing the MAP4 the 
-binding domain; Addgene Plasmid # 54152) were 
from the Michael Davidson plasmid collection. 
Tau(4H>K) and (4H>A) mutations were 
constructed as gene blocks (Integrated DNA 
Technologies) and inserted into the wildtype 
pmEmerald-MAPTau-C-10 plasmid using Gibson 
assembly. For bacterial expression, full length 
0N3R tau was subcloned into a pET28a bacterial 
expression vector using Gibson assembly 
containing an N-terminal 6xHis-tag. sfGFP-tau 
was constructed with an N-terminal 6xHis-tag and 
tandem Strep-tags connected by a GS-linker, 
followed by sfGFP, a precision protease cleavage 
site, and the 0N3R tau sequence. 
Tau proteins were expressed in BL21(DE3) E. 
coli cells in Luria Broth after induction with 0.4-1 
mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) overnight at 18°C. For 6xHis-tau, bacteria 
pellets were lysed by sonication on ice in 50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT and 
protease inhibitors. 6xHis-tau was purified by 
affinity chromatography on Ni-NTA resin, eluted 
into 50 mM Tris-HCl pH 7.8, 200 mM NaCl, 200 
mM imidazole, then dialyzed into 20 mM Tris-
HCl pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM 
DTT. For sfGFP-tau, bacteria pellets were 
resuspended in 50 mM Tris-HCl pH 8.0, 2 mM 
MgCl2, 1mM EGTA, and 10% glycerol and lysed 
using an Emulsiflex C3 (Avestin). sfGFP-tau was 
purified by affinity chromatography on Strep XT 
beads (IBA Lifesciences), followed by anion 
exchange chromatography on a HiTrap Q HP 
column in 50 mM Tris-HCl pH 7.5, 2 mM MgCl2, 
1mM EGTA, and 10% glycerol with a linear salt 
gradient from 100 mM to 400 mM, and finally by 
size exclusion chromatography on a Superose 6 in 
50 mM Tris-HCl pH 8.0, 2 mM MgCl2, 1mM 
EGTA, and 10% glycerol. Tau proteins were 
concentrated to ~50 µM, and aliquots were flash 
frozen in liquid N2 and stored at -80°C. 
In vitro MT-binding assays – Paclitaxel-
stabilized MTs were prepared by polymerizing 
25 μM purified porcine or bovine tubulin in 80 
mM K-PIPES pH 6.8, 5 mM MgCl2, 1 mM 
EGTA, 33% glycerol and 1 mM GTP at 37 °C. 
After 30 min MTs were stabilized by addition of 
50 µM paclitaxel.  
To test MT-binding of histidine mutants, 100 
nM tau protein was incubated with 1 µM MTs in 
250 µl BRB80 (80 mM K-PIPES pH 6.8, 1 mM 
MgCl2, 1 mM EGTA) with 1 mM DTT, 10 µM 
paclitaxel, and 10 µg/ml BSA. For testing pH-
sensitive MT-binding in vitro, we instead used a 
MOPS-based buffer with improved buffering 
capacity in the physiological pH range (20 mM 
MOPS, 0.1 mM EDTA, 0.1 mM EGTA, 5 mM 
magnesium acetate, 50 mM potassium acetate) 
with 1mM DTT, 10 μM paclitaxel, and 10 μg/ml 
BSA. The MOPS buffer pH was adjusted to 7.2 
and 8.0, respectively. pH values reported on the 
figures were measured after adding buffer 
equivalent to the amounts of MTs and tau added, 
which lowered the pH in the binding reactions by 
0.1-0.2 pH units. For reactions with 10 nM tau, the 
volume was doubled to 500 µl. After 20 min 
incubation at room temperature, MT-binding 
reactions were overlaid onto 400-600 µl of BRB80 
or the MOPS-based buffer with 10 µM paclitaxel 
containing 60% w/v glycerol and centrifuged in a 
Beckman TLA 100.2 rotor at 50,000 rpm for 20 
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min at 25°C. After centrifugation a portion of the 
supernatant (S) was saved for analysis, the cushion 
carefully washed with ddH2O to minimize 
contamination of the pellet and removed, and the 
pellet (P) resuspended in SDS-PAGE sample 
buffer. Equivalent amounts of supernatant and 
pellet were analyzed by SDS-PAGE on 4-12% 
NuPage gels (Invitrogen) and immunoblotting 
with a tau antibody (E-4, sc-515539; Santa Cruz 
Biotechnology). Coomassie-stained gels and 
chemiluminescent immunoblots were imaged with 
a FluorChem Q gel documentation system (92-
14116-00, Alpha Innotech). The MT-bound tau 
fraction was calculated as (IP-Ibkg)/(IS+IP-Ibkg). 
To determine dissociation constants using 
sfGFP-tau fluorescence, MTs were diluted in a 1:2 
dilution series into 10 µl BRB80 with 10 µM 
paclitaxel and mixed with 50 nM sfGFP-tau in 200 
µl MOPS buffer with DTT, paclitaxel and BSA as 
above in 500 µl Eppendorf tubes with the lids cut 
off. After 20 min incubation at room temperature, 
the tubes with the binding reactions were set into 
TLA 100.2 polycarbonate tubes and centrifuged as 
above, but without a glycerol cushion. 150 µl 
supernatant was then directly transferred from the 
centrifuge tube into a 100 µl Sub-MicroQuartz 
Fluorometer Cell (Starna Cells, Inc.) to minimize 
sfGFP-tau loss through unspecific adhesion to 
plastic. After removing the remainder of the 
supernatant, MT pellets were resuspended in 200 
µl ice-cold MOPS buffer without paclitaxel. 
sfGFP-tau fluorescence (F) was measured with a 
SpectraMax M5 plate reader (Molecular 
Dynamics, Sunnyvale, CA) at  λEx = 480 nm and 
λEm = 520 nm. The fraction of MT-bound sfGFP-
tau (fbnd) for each MT concentration was 
calculated as the average of (Ftot-FS)/Ftot in which 
Ftot is the fluorescence in the supernatant with no 
MTs, and FP/(FS+FP). Curve fitting with a binding 
isotherm fbnd = bmaxꞏ[MT]/(Kd+[MT]) was done in 
MATLAB (MathWorks). 
Cell culture, live cell imaging and analysis – 
Retinal pigment epithelial (RPE) cells were 
maintained in RPMI medium (Invitrogen) 
supplemented with 10% fetal bovine serum 
(Atlanta Biosciences) and 1% Glutamax 
(Invitrogen) at 37°C, 5% CO2. MCF10A cells 
stably expressing ER-RASV12 were maintained as 
described (37). For transient protein expression 
and microscopy, cells were plated in 35 mm glass-
bottom dishes (MatTek), transfected after 24 h 
using Fugene6 (Promega) and 1 µg plasmid DNA, 
and used for experiments 24 h later after replacing 
the transfection medium.  
To determine the pH response of tau MT-
binding in cells, the tissue culture medium was 
replaced with 25 mM Na-HEPES pH 7.4, 140 mM 
NaCl, 5 mM KCl, 10 mM glucose, 1 mM MgSO4, 
1 mM K2HPO4/KH2PO4 (pH 7.4), and 2 mM 
CaCl2. Cells were imaged on an environmentally 
controlled spinning disk confocal system as 
described (57, 58). After 3-5 images in the control 
HEPES pH 7.4 buffer, the buffer was replaced 
with the same buffer either containing 20 mM 
NH4Cl or 100 mM NaCl. After 5-10 min the 
buffer was once again replaced with control 
HEPES buffer. Intracellular pH changes with these 
treatments were determined in parallel in 
untransfected cells loaded with 2,7-
biscarboxyethyl-5(6)-carboxyfluorescein 
(BCECF) essentially as described (34, 35). 
BCECF fluorescence at λEm = 530 nm at two 
different excitation wavelengths (λEx = 440 nm and 
490 nm) were acquired using the SpectraMax M5 
plate reader and calibrated to cells treated with 10 
µM of the proton ionophore nigericin (Invitrogen) 
at pH 7.5 and pH 6.6. 
To indirectly analyze the amount of MT-
bound tau at different pHi values, we measured the 
mEmerald-tau fluorescence in the cytoplasm, 
which increases if less tau is MT-bound. 
mEmerald fluorescence intensity was measured in 
three small regions-of-interest (ROIs) per cell in 
three different time-points on the unprocessed 16-
bit images per buffer condition, and as necessary, 
the ROIs were moved slightly between images to 
avoid MT movements. ROI intensities were 
corrected for photobleaching or potential pH-
dependent changes in mEmerald fluorescence by 
normalizing to the total cell fluorescence in the 
first captured image. Normalization to the first 
time point also preserved variability between 
measurements. The relative amount of MT-bound 
tau mutants was quantified as described (33). All 
image analysis was done in NIS Elements version 
4.3 or higher (Nikon). Significance of multiple 
comparisons was calculated by Tukey–Kramer 
honest significant difference (HSD) test in 
Analyse-It for Microsoft Excel. Figures were 
assembled in Adobe Illustrator CS5, and videos 
were made using Apple QuickTime Pro. Box-and-
whisker plots show median, first and third quartile, 
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observations within 1.5 times the interquartile 
range, and all individual data points.  
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Figure 1. Molecular dynamics simulation of protonation effects on tau His299 interaction with the 
MT surface. (A) View of the MT-bound tau R2 MT-binding repeat from the MT outside based on the 
recent cryo-EM structure (PDB ID: 6CVN). The tubulin surface is colored by electrostatic potential 
highlighting the strongly negative surface charge or the protofilament ridge. (B) Last frames of 5 ns MD 
simulations of protonated His299+ (i.e. low pH; orange) and unprotonated His2990 (high pH; blue) 
compared with the cryo-EM structure (grey). A side view of the tubulin protofilament is shown with tau 
R2 on top. (C) Close-up views of the binding pocket surrounding His299. (D) Sequence alignment of 
MT-binding repeats in all members of the human MAP2/tau family indicating the high degree of 
conservation of the histidine residue in the position equivalent to His299 in tau R2 (asterisk).  
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Figure 2. Increased pH decreases tau binding to MTs in vitro. (A) Co-sedimentation assay of 100 nM 
0N3R tau protein with 0.5 µM paclitaxel-stabilized MTs. Shown are immunoblots for tau and Coomassie-
stained gels for tubulin in the supernatant and pellet at the indicated pH values. Note that tau remains in 
the supernatant in the absence of MTs at both pH values. The boxplot shows a quantification of the tau 
fraction recovered in the pellet (n = 5). (B) Equilibrium binding of 50 nM fluorescently tagged 0N3R 
sfGFP-tau protein at a range of MT concentrations between 15.6 nM and 1 µM at the indicated pH values. 
The fraction bound was determined by MT co-sedimentation of fluorescently tagged 0N3R sfGFP-tau and 
measuring sfGFP-tau fluorescence in the supernatant and pellet. Grey symbols show each data point and 
black symbols are the average for each MT concentration. The black line shows a hyperbolic fit through 
data from all experiments and the grey area indicates the 95% confidence interval of the fit. The boxplot 
shows dissociation constants obtained when each experiment was fitted independently (n = 4). Box plots 
show median, first and third quartile, with whiskers extending to observations within 1.5 times the 
interquartile range, and all individual data points. Statistical analysis by Student t-test.  
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Figure 3. Increased intracellular pH decreases tau binding to MTs. (A) RPE cells transiently 
expressing either fluorescently tagged 0N3R tau (top row) or tubulin (bottom row) treated with 20 mM 
NH4Cl to acutely increase pHi in the cytoplasm. Insets show highlighted regions at higher magnification. 
(B) Quantification of the mEmerald-tau or EGFP-tubulin fluorescence in the cytoplasm (n = 13 cells 
each). Note that elevated pH increases mEmerald-tau signal in the cytoplasm almost 2-fold, which 
indicates dissociation from MTs. Box plots show median, first and third quartile, with whiskers extending 
to observations within 1.5 times the interquartile range, and all individual data points. Statistical analysis 
by Tukey-Kramer HSD test. 
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Figure 4. Increased intracellular pH decreases binding of MAP2/tau family proteins to MTs. (A) 
RPE cells transiently expressing either mEmerald-tagged tau (top row) or -MAP4 (bottom row) treated 
with 100 mM NaCl to acutely increase pHi in the cytoplasm. Insets show highlighted regions at higher 
magnification. (B) Quantification of the mEmerald-tau or -MAP4 fluorescence in the cytoplasm (tau: n = 
19; MAP4: n = 13 cells). Both MAP2/tau family proteins reversibly dissociate from MTs at increased 
pHi. Note that MAP4 expression generally results in some degree of MT bundling, and MAP4 does not 
completely disappear from these bundles, but mEmerald-MAP4 in the cytoplasm is notably increased at 
increased pHi. Box plots show median, first and third quartile, with whiskers extending to observations 
within 1.5 times the interquartile range, and all individual data points. Statistical analysis by Tukey-
Kramer HSD test. 
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Figure 5. Decreasing pHi in cancer cells enhances tau binding to MTs. (A) MCF10A mammary 
epithelial cells expressing oncogenic H-RasV12 before and after treatment with a nigericin buffer to 
equilibrate pHi to 7.2. Inset shows highlighted regions at higher magnification. (B) Quantification of the 
relative mEmerald-tau fluorescence in the cytoplasm (n = 15 cells). Box plot shows median, first and 
third quartile, whiskers extending to observations within 1.5 times the interquartile range, and all 
individual data points. Statistical analysis by Student t-test. 
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Figure 6. Conserved histidine residues modulate pH-dependent tau binding to MTs. (A) Close-up 
views of 5 ns MD simulations in which tau R2 His299 was substituted with either lysine or alanine as 
indicated overlaid with the cryo-EM structure shown in grey. (B) Co-sedimentation assay of 100 nM 
0N3R tau protein with the indicated substitutions of conserved histidine residues with 1 µM paclitaxel-
stabilized MTs at pH 6.8. Shown are immunoblots for tau and Coomassie-stained gels for tubulin in the 
supernatant and pellet. Note that tau remains in the supernatant in the absence of MTs. The boxplot shows 
a quantification of the tau fraction recovered in the pellet (n = 5). (C) Co-sedimentation assay of 10 nM 
0N3R tau protein or 10 nM tau(4H>K) with 1 µM paclitaxel-stabilized MTs. Because tau is too diluted to 
be accurately detected in the supernatant only pellets of two independent experiments for each tau 
construct at the indicated pH values are shown. Equivalent amounts of pellets from different experiments 
were run in adjacent lanes on the same gels to minimize experimental error. The boxplot shows the ratio 
of either tubulin or tau in the pellet at pH 7.8 compared with pH 7.1 (wt: n = 4; 4H>K: n = 3). Statistical 
analysis by Tukey-Kramer HSD test.  
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Figure 5. Conserved histidine residues are required for tau binding to MTs in cells. (A) RPE cells 
transiently expressing the indicated mEmerald-tagged tau constructs. Insets show highlighted regions at 
higher magnification. (B) Quantification of the relative enrichment of the indicated mEmerald-tau 
constructs on MTs compared to cytoplasm signal (wt and 4H>K: n = 14; 4H>A: n = 6 cells). The dashed 
line at a MT to cytoplasm ratio of one represents undetectable MT binding. Box plot shows median, first 
and third quartile, with whiskers extending to observations within 1.5 times the interquartile range, and all 
individual data points. Statistical analysis by Tukey-Kramer HSD test. 
 
